Induction of CMV-specific T-cell lines using Ag-presenting cells pulsed with CMV protein or peptide

By Einsele H   Rauser G   Grigoleit U   Hebart H   Sinzger C   Riegler S   Jahn G  

Cytotherapy, Vol. 4, Iss. 1, 2002-01 ,pp. : 49-54

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Clinical trials with CMV-specific T cells

By Peggs KS   Mackinnon S  

Cytotherapy, Vol. 4, Iss. 1, 2002-01 ,pp. : 21-28

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy

By Jensen Mc   Cooper Ljn   Wu Am   Forman Sj   Raubitschek A  

Cytotherapy, Vol. 5, Iss. 2, 2003-01 ,pp. : 131-138

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene

By Lamers Chj   van Elzakker P   Langeveld Scl   Sleijfer S   Gratama Jw  

Cytotherapy, Vol. 8, Iss. 6, 2006-12 ,pp. : 542-553

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease

By Hobeika Ac   Osada T.   Serra D.   Peplinski S.   Hanson K.   Tanaka Y.   Niedzwiecki D.   Chao N.   Rizzieri D.   Lyerly Hk   Clay T.   Morse Ma  

Cytotherapy, Vol. 10, Iss. 3, 2008-01 ,pp. : 289-302

Ashgate Publishing Ltd

Access to resources Recommend Favorite